Effects of Cholinergic Stimulation with Pyridostigmine Bromide on Chronic Chagasic Cardiomyopathic Mice

Table 3

Heart rate variability after treatment with pyridostigmine bromide. Heart rate variability parameters (expressed as mean ± S.E.M.) collected at the 6th month of observation and after one month of treatment (from the 5th to 6th month of infection) in noninoculated control (Con) or T. cruzi-inoculated (Chg) freely moving C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or vehicle (NT: nontreated animals).

	Con-NT	Con-Pyrido	Chg-NT	Chg-Pyrido
RR (ms)	117.97 ± 3.97	112.67 ± 4.14	104.27 ± 4.32	113.74 ± 4.33
HR (bpm)	516.81 ± 8.35	543.57 ± 9.06	590.61 ± 9.82	539.07 ± 8.76
Variance (ms^2)	218.61 ± 12.35	148.96 ± 9.91	32.13 ± 5.12^*&	63.57 ± 6.11
VLF (ms^2)	106.06 ± 8.93	69.37 ± 7.23	11.76 ± 2.84^*&	22.60 ± 3.90
LF (ms^2)	57.84 ± 6.28	52.31 ± 6.23	11.10 ± 3.77*	21.99 ± 5.09
LF (nu)	51.83 ± 4.13	56.24 ± 4.09	47.80 ± 4.57	39.25 ± 4.91
HF (ms^2)	54.71 ± 6.86	27.19 ± 4.44	9.01 ± 3.19^*&	18.78 ± 3.53
HF (nu)	47.54 ± 4.11	41.80 ± 3.97	48.05 ± 4.49	58.70 ± 4.86
LF/HF	2.31 ± 1.53	4.04 ± 1.48	2.60 ± 1.54	2.92 ± 2.01

RR: RR interval; HR: heart rate; VLF: very low frequency spectral component; LF: low frequency spectral component; HF: high frequency spectral component; ms: milliseconds; bpm: beats per minute; nu: normalized units; versus Con-NT; and versus Chg-Pyrido.